John E. Davis Sells 6,457 Shares of Artivion, Inc. (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) insider John E. Davis sold 6,457 shares of the business’s stock in a transaction on Monday, February 24th. The shares were sold at an average price of $27.31, for a total transaction of $176,340.67. Following the completion of the transaction, the insider now owns 160,631 shares in the company, valued at approximately $4,386,832.61. The trade was a 3.86 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Artivion Price Performance

Shares of NYSE AORT opened at $25.34 on Friday. The firm’s 50-day moving average price is $29.58 and its 200-day moving average price is $27.80. Artivion, Inc. has a 1-year low of $18.38 and a 1-year high of $32.33. The firm has a market capitalization of $1.06 billion, a P/E ratio of -1,267.00 and a beta of 1.75. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71.

Artivion (NYSE:AORT) last announced its quarterly earnings data on Monday, February 24th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.51). The company had revenue of $97.31 million for the quarter, compared to analyst estimates of $100.82 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. Equities research analysts anticipate that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Analysts Set New Price Targets

AORT has been the topic of several recent analyst reports. Oppenheimer boosted their target price on shares of Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a report on Friday, November 8th. JMP Securities restated a “market outperform” rating and issued a $33.00 target price on shares of Artivion in a report on Tuesday, December 10th. Needham & Company LLC dropped their price objective on shares of Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Stifel Nicolaus dropped their price objective on shares of Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a report on Tuesday. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $31.40.

Institutional Investors Weigh In On Artivion

Hedge funds and other institutional investors have recently made changes to their positions in the business. Smartleaf Asset Management LLC increased its position in shares of Artivion by 236.7% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,118 shares of the company’s stock worth $32,000 after acquiring an additional 786 shares in the last quarter. Quarry LP increased its position in shares of Artivion by 210.8% during the third quarter. Quarry LP now owns 1,209 shares of the company’s stock worth $32,000 after acquiring an additional 820 shares in the last quarter. R Squared Ltd bought a new stake in shares of Artivion during the fourth quarter worth about $39,000. Arcadia Investment Management Corp MI bought a new stake in shares of Artivion during the fourth quarter worth about $43,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Artivion during the fourth quarter worth about $64,000. 86.37% of the stock is owned by institutional investors.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.